Werewolf Therapeutics reports Q4 2023 net loss $12M; CSO retiring March 29, 2024

Werewolf Therapeutics, Inc.

Net loss of $12.0M in Q4 2023 ($37.4M full year) vs $11.9M in Q4 2022.
Cash and equivalents $134.3M plus restricted cash $21.2M as of Dec 31, 2023.
Cash runway extended through Q2 2025, including $17.7M ATM proceeds in early 2024.
Collaboration revenue from Jazz fell to $1.5M Q4 from $7.3M year ago.
CSO Cynthia Seidel-Dugan retiring effective March 29, 2024.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Cynthia Seidel-Dugan

Chief Scientific Officer

HOWL · Werewolf Therapeutics, Inc.

Effective: 2024-03-29
Filed: March 7, 2024, 6:59 PM ET

On March 3, 2024, Cynthia Seidel-Dugan, Ph.D., notified the Company of her intent to retire from her position as Chief Scientific Officer of the Company, effective as of March 29, 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Werewolf Therapeutics, Inc. reported quarter ended December 31, 2023 results: revenue $1.5 million.

Period: quarter ended December 31, 2023
Revenue: $1.5 million
Result: reported results

Exact text from the filing

Collaboration revenue was $1.5 million for the fourth quarter of 2023, compared to $7.3 million for the same period in 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Cynthia Seidel-Dugan departed as Chief Scientific Officer at Werewolf Therapeutics, Inc..

Action: retire
Role: Chief Scientific Officer

Exact text from the filing

On March 3, 2024, Cynthia Seidel-Dugan, Ph.D., notified the Company of her intent to retire from her position as Chief Scientific Officer of the Company, effective as of March 29, 2024.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001785530-24-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.